Biography
Matt’s recent experience includes serving on Weil teams representing:
- Regeneron Pharmaceuticals in a Delaware federal antitrust lawsuit, securing a $407 million jury verdict against competitor Amgen, Inc. for unlawfully monopolizing the U.S. market for PCSK9 inhibitor drugs by leveraging sales of anti-inflammatory drugs Enbrel and Otezla to boost sales of its PCSK9i Repatha and shutting out Regeneron’s PCSK9i Praluent.
- The International Association of Scientific, Technical, and Medical Publishers (STM) in an antitrust class action alleging a conspiracy between STM and member publishers regarding compensation for peer reviewers and manuscript submission to publications.
Matt maintains an active pro bono practice that includes a wide variety of work, including serving on a Weil team co-representing deaf and hard-of-hearing individuals as plaintiffs seeking accessibility accommodations in Georgia state prisons; drafting and supporting amicus briefs in collaboration with academic scholars and non-profit organizations in LGBTQ+ rights litigations in federal courts and the Supreme Court; and assisting local New Yorkers with legal name change petitions and SNAP benefit applications.
Matt received his J.D., cum laude, from Tulane University Law School, where he served in the law school’s Civil Rights and Federal Practice Clinic and as a member of the Tulane Law Review. He received his B.S., summa cum laude, in Criminology and French from Florida State University.